10X Genomics Inc (TXG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 10X Genomics Inc (TXG) has a cash flow conversion efficiency ratio of 0.021x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($16.97 Million) by net assets ($825.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 10X Genomics Inc (TXG) total market value for the company's overall valuation and market capitalisation.
10X Genomics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how 10X Genomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
10X Genomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 10X Genomics Inc ranked by their cash flow conversion efficiency. Explore TXG cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Booz Allen Hamilton Holding
NYSE:BAH
|
0.234x |
|
Ackermans & Van Haaren NV
BR:ACKB
|
0.060x |
|
Nordnet AB
ST:SAVE
|
0.990x |
|
AZUL SA PFD ADR 1
F:8AZA
|
N/A |
|
NIBE Industrier AB (publ)
ST:NIBE-B
|
0.035x |
|
Yunnan Lincang Xinyuan Germanium Industrial Co Ltd
SHE:002428
|
-0.025x |
|
Pilbara Minerals Ltd
AU:PLS
|
0.044x |
|
NIO INC. CL. A DL -00025
F:N3I
|
N/A |
Annual Cash Flow Conversion Efficiency for 10X Genomics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of 10X Genomics Inc from 2017 to 2025. View 10X Genomics Inc (TXG) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $796.33 Million | $136.05 Million | 0.171x | +1720.59% |
| 2024-12-31 | $710.13 Million | $6.66 Million | 0.009x | +145.76% |
| 2023-12-31 | $741.04 Million | $-15.20 Million | -0.021x | +50.83% |
| 2022-12-31 | $805.74 Million | $-33.61 Million | -0.042x | -59.54% |
| 2021-12-31 | $817.57 Million | $-21.37 Million | -0.026x | +91.13% |
| 2020-12-31 | $739.07 Million | $-217.90 Million | -0.295x | -457.67% |
| 2019-12-31 | $420.08 Million | $34.63 Million | 0.082x | -76.27% |
| 2018-12-31 | $-219.99 Million | $-76.41 Million | 0.347x | +265.25% |
| 2017-12-31 | $-112.51 Million | $-10.70 Million | 0.095x | -- |
About 10X Genomics Inc
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related… Read more